Almirall Plots M&A Moves Ahead Of Lebrikizumab Approval

Raises €200m For Bolt-Ons Or Licensing

The Spanish group has been fairly quiet on the dealmaking front of late but the proceeds of a significant capital raise have been earmarked to help “swiftly execute inorganic growth opportunities.”

Almirall
• Source: Almirall

Most of the focus at Almirall SA is on securing EU approval for the closely watched atopic dermatitis drug lebrikizumab but the Spanish drugmaker is also looking to bring in other assets to feed the pipeline.

As part of that strategy, Almirall has closed a €200m capital raise through the issue of around 24.4 million new...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.